• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace Home
  • TIP FAKÜLTESİ
  • Makale
  • Web of Science İndeksli Yayınlar
  • View Item
  •   DSpace Home
  • TIP FAKÜLTESİ
  • Makale
  • Web of Science İndeksli Yayınlar
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Three critical clinicobiological phases of the human SARS-associated coronavirus infections

Thumbnail
Date
2020
Author
Turk, C. and Turk, S. and Malkan, U. Y. and Haznedaroglu, I. C.
xmlui.mirage2.itemSummaryView.MetaData
Show full item record
Abstract
OBJECTIVE: COVID-19 immune syndrome is a multi-systemic disorder induced by the COVID-19 infection. Pathobiological transitions and clinical stages of the COVID-19 syndrome following the attack of SARS-CoV-2 on the human body have not been fully explored. The aim of this review is to outline the three critical prominent phase regarding the clinicogenomics course of the COVID-19 immune syndrome. MATERIALS AND METHODS: In the clinical setting, the COVID-19 process presents as ``asymptomatic/pre-symptomatic phase. ``respiratory phase with mild/moderate/severe symptoms{''} and ``multi-systemic clinical syndrome with impaired/disproportionate and/or defective immunity{''}. The corresponding three genomic phases include the ``ACE2. ANPEP transcripts in the initial phase{''}, ``EGFR and IGF2R transcripts in the propagating phase{''} and the ``immune system related critical gene involvements of the complicating phase{''}. RESULTS: The separation of the phases is important since the genomic features of each phase are different from each other and these different mechanisms lead to distinct clinical multi-systemic features. Comprehensive genomic profiling with next generation sequencing may play an important role in defining and clarifying these three unique separate phases for COVID-19. From our point of view. it is important to understand these unique phases of the syndrome in order to approach a COVID-19 patient bedside. CONCLUSIONS: This three-phase approach may be useful for future studies which will focus on the clinical management and development of the vaccines and/or specific drugs targeting the COVID-19 processes. ANPEP gene pathway may have a potential for the vaccine development. Regarding the specific disease treatments, MAS agonists, TXA127, Angiotensin (1-7) and soluble ACE2 could have therapeutic potential for the COVID-19 course. Moreover, future CRISPR technology can be utilized for the genomic editing and future management of the clinical course of the syndrome.
URI
http://hdl.handle.net/20.500.12591/212
xmlui.mirage2.itemSummaryView.Collections
  • Web of Science İndeksli Yayınlar





Creative Commons License
DSpace@LokmanHekim by Lokman Hekim University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV
 

 



About HUAES
Open Access PolicyOpen Access InstructionGuidesSubcriptionsContact
sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV